{"disease":{"id":"glioma","name":"glioma"},"drugs":{"marketed":[{"drug_id":"belzutifan","indication_name":"Pheochromocytoma or Paraganglioma (PPGL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Welireg","generic_name":"BELZUTIFAN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"HIF-2α","drug_class":"Hypoxia-inducible Factor Inhibitor [EPC]","quality_score":75,"revenue":"509","mechanism":"Belzutifan inhibits HIF-2α, blocking its interaction with HIF-1β to reduce expression of genes linked to tumor growth."},{"drug_id":"chembl-chembl2103875","indication_name":"BRAF V600E Mutation-Positive Low-Grade Glioma (Combination with Dabrafenib)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TRAMETINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":5,"revenue":null,"mechanism":null},{"drug_id":"neo-bladder-construct","indication_name":"BRAF V600E Mutation-Positive Low-Grade Glioma in Pediatric Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"\"Neo-Bladder\" Construct","company_name":"Wake Forest University Health Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":29,"revenue":null,"mechanism":null},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic glioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic paraganglioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"dordaviprone","indication_name":"diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Modeyso","generic_name":"DORDAVIPRONE","company_name":"Chimerix","drug_phase":"marketed","molecular_target":"Dopamine","drug_class":"Protease Activator [EPC]","quality_score":57,"revenue":null,"mechanism":"Modeyso works by binding to dopamine receptors in the brain, which helps to slow the growth of cancer cells."},{"drug_id":"dordaviprone","indication_name":"diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Modeyso","generic_name":"DORDAVIPRONE","company_name":"Chimerix","drug_phase":"marketed","molecular_target":"Dopamine","drug_class":"Protease Activator [EPC]","quality_score":57,"revenue":null,"mechanism":"Modeyso works by binding to dopamine receptors in the brain, which helps to slow the growth of cancer cells."},{"drug_id":"carmustine","indication_name":"Glioma, malignant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gliadel","generic_name":"CARMUSTINE","company_name":"Avet Lifesciences","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"Alkylating Drug","quality_score":10,"revenue":null,"mechanism":"Gliadel works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow."},{"drug_id":"azedra","indication_name":"Paraganglioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Azedra","company_name":"David Bushnell","drug_phase":"discontinued","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"temodal","indication_name":"Glioma, malignant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Temodal","company_name":"Armando Santoro, MD","drug_phase":"phase_1","molecular_target":"","drug_class":"","quality_score":3,"revenue":null,"mechanism":null},{"drug_id":"sitravatinib","indication_name":"Malignant glioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sitravatinib","generic_name":"sitravatinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine kinases","drug_class":"Tyrosine kinase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"carmustin","indication_name":"Glioma, malignant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carmustin","company_name":"University Hospital Freiburg","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"vorasidenib","indication_name":"Grade 2 oligodendroglioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Voranigo","generic_name":"VORASIDENIB","company_name":"Servier","drug_phase":"marketed","molecular_target":"","drug_class":"Isocitrate Dehydrogenase 1 Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Voranigo works by blocking the activity of an enzyme called isocitrate dehydrogenase 1."},{"drug_id":"tovorafenib","indication_name":"relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ojemda","generic_name":"TOVORAFENIB","company_name":"Day One Biopharms","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Ojemda works by blocking the BRAF protein, which is a key driver of cancer cell growth and survival."},{"drug_id":"tovorafenib","indication_name":"relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ojemda","generic_name":"TOVORAFENIB","company_name":"Day One Biopharms","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Ojemda works by blocking the BRAF protein, which is a key driver of cancer cell growth and survival."},{"drug_id":"temozolomide","indication_name":"Glioma, malignant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Temodar","generic_name":"temozolomide","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Temodar works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."}],"pipeline":[],"offLabel":[],"totalMarketed":16,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05859659","title":"Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)","phase":"","overall_status":"RECRUITING","enrollment_count":70000,"lead_sponsor_name":"Yaou Liu","has_results":false},{"nct_id":"NCT00418899","title":"Gliogene: Brain Tumor Linkage Study","phase":"","overall_status":"UNKNOWN","enrollment_count":17080,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01772771","title":"Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06199388","title":"Development and Validation of a Deep Learning-Based Survival Prediction Model for Pediatric Glioma Patients: A Retrospective Study Using the SEER Database and Chinese Data","phase":"","overall_status":"COMPLETED","enrollment_count":9532,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07072143","title":"An International Study on Pediatric Patients With Rare Tumors.","phase":"","overall_status":"RECRUITING","enrollment_count":6250,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT04215224","title":"Histopathology Images Based Survival Prediction of Glioma Patients Using Artificial Intelligence","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT00009035","title":"Natural History of Patients With Brain and Spinal Cord Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":3050,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04216537","title":"Survival Significance of Molecular Pathology and Genetic Variation in Brain Gliomas","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT04217018","title":"MR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT04217044","title":"Histopathology Images Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT05254197","title":"SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT07198256","title":"AI-assisted Diagnosis of Malignant Brain Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04215211","title":"MR Based Survival Prediction of Glioma Patients Using Artificial Intelligence","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT03160274","title":"Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"The University of Texas Health Science Center at San Antonio","has_results":false},{"nct_id":"NCT07263711","title":"Prospective Real-World Study of Pathology AI for Glioma Molecular Prediction","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT00339352","title":"A Family Study of Adults With Glioma","phase":"","overall_status":"COMPLETED","enrollment_count":1871,"lead_sponsor_name":"National Institutes of Health Clinical Center (CC)","has_results":false},{"nct_id":"NCT05259605","title":"Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification","phase":"","overall_status":"RECRUITING","enrollment_count":1650,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT04648462","title":"Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Maastricht Radiation Oncology","has_results":false},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06408402","title":"Impact of Environmental Exposures on Tumor Risk in SDHx-mutation Carriers","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1300,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05635435","title":"Immune and Inflammatory Indices in Peripheral Blood Predict Prognosis of Glioma and Correlate With Grades and Subtypes","phase":"","overall_status":"UNKNOWN","enrollment_count":1282,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT00919750","title":"Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":1258,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT05100173","title":"Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1192,"lead_sponsor_name":"Genetron Health","has_results":false},{"nct_id":"NCT05100602","title":"Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1192,"lead_sponsor_name":"Genetron Health","has_results":false},{"nct_id":"NCT03344016","title":"Multicenter Pheochromocytoma and Paraganglioma Evaluation","phase":"NA","overall_status":"RECRUITING","enrollment_count":1148,"lead_sponsor_name":"Felix Beuschlein","has_results":false},{"nct_id":"NCT03750890","title":"Visual Study of Molecular Genotype in Glioma Evolution","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT07448480","title":"Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Blokhin's Russian Cancer Research Center","has_results":false},{"nct_id":"NCT06377033","title":"Using the EHR to Advance Genomic Medicine Across a Diverse Health System","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT04274283","title":"Tessa Jowell BRAIN MATRIX - Platform Study","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT04469244","title":"Evaluation of the Use of Radiomics in 18F-FDOPA PET Examinations for the Characterization of Gliomas","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT06472440","title":"Evaluation of the Use of a Method \"Radiomics\" for DOPA PET in Gliomas","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT04025541","title":"Analysis of Circulating Tumor Markers in Blood","phase":"NA","overall_status":"RECRUITING","enrollment_count":992,"lead_sponsor_name":"Institut du Cancer de Montpellier - Val d'Aurelle","has_results":false},{"nct_id":"NCT04924127","title":"Molecular Pathology Research Project of Glioma","phase":"","overall_status":"COMPLETED","enrollment_count":976,"lead_sponsor_name":"Jinsong Wu","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03583528","title":"DOTATOC PET/CT for Imaging NET Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT06914700","title":"A Nomogram for Predicting the Diagnosis of Central Malignant Tumors Based on Preoperative Clinical Characteristics and Laboratory Indicators:","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT05464992","title":"Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI","phase":"NA","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Centre Paul Strauss","has_results":false},{"nct_id":"NCT06118723","title":"The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)","phase":"","overall_status":"RECRUITING","enrollment_count":784,"lead_sponsor_name":"Jasper Gerritsen","has_results":false},{"nct_id":"NCT00035373","title":"Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols","phase":"","overall_status":"TERMINATED","enrollment_count":767,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03849430","title":"Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT06523582","title":"Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Universidad Nacional Autonoma de Mexico","has_results":false},{"nct_id":"NCT03722355","title":"Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":712,"lead_sponsor_name":"Radiation Therapy Oncology Group","has_results":false},{"nct_id":"NCT00031538","title":"Genetic Analysis of Brain Tumors","phase":"","overall_status":"TERMINATED","enrollment_count":674,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04216550","title":"Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT07236840","title":"Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Tata Memorial Centre","has_results":false},{"nct_id":"NCT07450872","title":"Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"The Children's Hospital of Zhejiang University School of Medicine","has_results":false},{"nct_id":"NCT02300532","title":"Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)","phase":"","overall_status":"COMPLETED","enrollment_count":561,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}